DOW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dow Inc is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 who is impatient and wants an immediate decision. The stock has some supportive catalysts and reasonable analyst support, but the current technical setup is still weak and the recent institutional selling trend is a meaningful drag. I would not buy aggressively at this moment; I would hold and wait for clearer price strength.
DOW closed at 34.71, just above the key support area near S1 at 34.683 and above S2 at 33.425. The MACD histogram is negative at -0.476 and still below zero, which confirms bearish momentum, though the negative move is contracting. RSI_6 at 22.294 shows the stock is very oversold, but not yet a clean bullish reversal signal. Moving averages are converging, which suggests the stock may be stabilizing, but the trend is not yet strong enough to call an active buy. Overall, the chart is weak-to-neutral with support being tested.
Positive catalysts include the Texas nuclear project receiving US Nuclear Regulatory Commission approval, which helps advance a longer-term strategic initiative. Dow also launched the DOWSIL TC-3120 Thermal Gel, adding a product-related growth catalyst in electronics. News around tighter petrochemical supply, Middle East disruptions, and improved polyethylene pricing has been supportive. Analyst sentiment has improved recently overall, with multiple firms raising targets or upgrading the stock. Congress trading data is mildly positive, with 1 recent purchase and no sales, indicating some favorable political interest.
The main negatives are continued weakness in chemical pricing, oversupply concerns, and evidence of demand destruction cited by Citi. Hedge funds are heavily selling, with selling activity up sharply over the last quarter, which is a notable institutional red flag. The stock is still technically under pressure and has not confirmed a strong reversal. The recent analyst target cut from Citi to $41 also shows that upside expectations are becoming more restrained.
No latest-quarter financial snapshot was available due to data error, so a detailed quarter-by-quarter assessment cannot be confirmed from the provided dataset. However, analyst commentary indicates Dow's Q1 earnings beat and better-than-expected Q1 results, with a robust Q2 guide driven by commodity momentum and cost actions. That suggests recent quarterly growth momentum improved, especially in pricing and operating leverage, though the broader company still faces cyclical pressure from chemical oversupply.
Analyst sentiment has improved overall in recent weeks, with Argus upgrading Dow to Buy, JPMorgan maintaining Overweight, RBC keeping Outperform and raising targets, and BMO raising its target after a Q1 beat. Deutsche Bank and UBS remain more cautious with Hold/Neutral-type stances. Citi recently lowered its target to $41 from $48 while keeping Buy, citing normalizing chemical prices and demand destruction. Wall Street’s pros view is that lower supply, cost actions, and pricing improvements could boost earnings; the cons view is that oversupply, weaker demand, and near-term rangebound trading limit conviction.
